Bristol Myers Squibb

Have you visited SurvivorshipToday.com lately? Since 2019, our Survivorship Today campaign has amplified the voices of the cancer survivorship community — exploring the challenges, triumphs and realities of life after diagnosis. This next chapter introduces new faces and fresh perspectives to the conversation. Take a glimpse at the content featured below and explore inspiring stories at SurvivorshipToday.com. #OneBMS

We’re looking forward to joining the global cardiovascular community at the American Heart Association (AHA) Scientific Sessions in New Orleans. Collaboration and connection are key to driving innovation in cardiovascular research, and #AHA25 provides an important forum to engage with peers, share perspectives and stay at the forefront of scientific progress. Discover how we’re helping shape the future of cardiovascular care: https://bit.ly/4nBge0b #OneBMS

We’re harnessing advanced neuroimaging technologies to unlock the complexities of the brain and accelerate the development of transformative treatments for neurological conditions. Using tools like MRI and PET, our scientists can non-invasively visualize the brain, track investigational medicines in real time and gain critical insights into disease processes. Explore how neuroimaging is shaping our approach to diseases like multiple sclerosis, Alzheimer’s disease, depression and schizophrenia: https://bit.ly/3Xdev6x #OneBMS

As we kick off Veteran and Military Appreciation Month at Bristol Myers Squibb, I’m reminded that our commitment to the military community is something we celebrate every day. In a time of great change, this year’s theme, “Thriving Through Transformation,” could not be more fitting. We in the military community experience constant change and learn how to navigate military life’s challenges. It is a superpower that makes us stand out and enables us to lift those around us.   What makes this month truly special is the opportunity to showcase all that we as the Veterans Community Network have accomplished throughout the year with our colleagues, partners, and friends. I’m especially looking forward to sharing the incredible stories of those who have served, are currently serving, and the families who support them and “hold down the fort” while they are away. As a Marine Corps veteran, sharing and hearing these personal stories contributes to the deep sense of camaraderie that we strive so hard to create throughout our company.   It’s also exciting to see our most senior leaders actively participate in honoring our heroes, leading the charge in demonstrating the deep respect and gratitude we have for the sacrifices made by our military community. Here’s to a month of celebration, reflection, and appreciation for all who serve and support! #BMS_Employee #ThrivingThroughTransformation #2025VeteransSalute

As part of our vision to transform patients’ lives through science, we are committed to addressing the needs of people living with neurological and neuropsychiatric conditions – pursuing bold science while always keeping patients at the center. Hear from Dr. Ken Kramer, PhD as our team prepares to attend the upcoming NEI Fall Congress, and learn more about our work in neuroscience: https://bit.ly/3X6bO6O #OneBMS

“Even though you’re CEO, you rely on the leverage that you get from your team and having a great team that works with you every single day.” As Chris Boerner begins his third year as CEO, he shares his learnings from the past two years in the latest episode of Trials to Transformation. #TrialstoTransformation #OneBMS

We're showcasing new data at #AHA25 highlighting how our legacy of bold science and cardiovascular innovation is advancing patient care. Explore the growing body of long-term and real-world data from our cardiovascular portfolio: https://bit.ly/4qEm045

Earlier today, we announced another quarter of strong earnings results, reflecting continued execution across the business as we progress our long-term growth strategy. In Q3, we built on momentum generated in the first half of the year, delivering another quarter of double-digit growth in our Growth Portfolio. We also achieved important clinical and regulatory milestones while enhancing our portfolio through business development. As we look toward year’s end, our focus remains on delivering transformational medicines for patients and driving sustainable growth. Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/3LkEpm9